970*90
768
468
mobile

The test, called Oncotype DX, analyses the samples of tumor that is removed during surgery

Franchise India Bureau
Franchise India Bureau Oct 03 2017 - 3 min read
The test, called Oncotype DX, analyses the samples of tumor that is removed during surgery
The test is suitable for women, who have a hormone-driven breast cancer type known as Oestrogen receptor positive HER2 negative which accounts for most breast cancer patients

Researchers have developed a new test that can predict the return of the cancer, thus sparing breast cancer patients from unnecessary chemotherapyThe test, called Oncotype DX, analyses the samples of tumour that is removed during surgery and provides a score between 1 and 100 on the likelihood of the cancer returning.

Professor Nigel Bundred, said a leading breast cancer surgeon at the hospital "Thousands of women are undergoing unnecessary chemotherapy because of the failure to make this available to everyone.”

The test is suitable for women, who have a hormone-driven breast cancer type known as Oestrogen receptor positive HER2 negative which accounts for most breast cancer patients.

For the study, published in the journal Clinical Oncology, the team conducted a trial, known as Plan B, and involved over 4,000 patients in 12 centres in Germany.

Plan B showed that the test was effective both in women whose cancer remained in the breast and in those patients whose cancer had spread to the lymph nodes.

Subscribe Newsletter
Submit your email address to receive the latest updates on news & host of opportunities
Entrepreneur Magazine

For hassle free instant subscription, just give your number and email id and our customer care agent will get in touch with you

or Click here to Subscribe Online

Newsletter Signup

Share your email address to get latest update from the industry